Outcomes of point-of-care manufactured CAR T cell therapy for B cell acute lymphoblastic leukemia and non-Hodgkin lymphoma in Vietnam

Molecular Therapy Oncology 2026 Open access

Read full text
Authors: Liem Thanh Nguyen, Duy T. Nguyen, Quoc Khanh Bach, Lan T.M. Dao, Trang Thi Kieu Phan, Hoang Dai Nghia Nguyen, Hong-Nhung Dao, Trang H. Pham, Phuong M.H. Pham, Hien T. Mai, Viet Huong T. Pham, Thanh Thi Nhat Nguyen
+9 more Van Binh Le, Nam Lam Phung, Ngoc Quang Nguyen, Michelle Lynn Hermiston, Quynh Lan Phan, Do Quang Trung Nguyen, Lan Mai, Quốc Nhật Nguyễn, V. Huy Hoang
DOI: 10.1016/j.omton.2026.201156
Cited by: 1
References: 38

Abstract

). Cytokine release syndrome (CRS) occurred in 13 patients (12 with grade 1-2, one with grade 3), and grade 1 neurotoxicity was observed in two patients. In ALL, the complete remission (CR) rates were 100% on day 30, 75% on day 90, and 62.5% on day 180. Patients with NHL showed CR rates of 87.5% on both day 90 and day 180. The estimated 1-year progression-free survival rates were 62.5% (95% confidence interval [CI]: 36.5%-100%) for ALL and 87.5% (95% CI: 67.3%-100%) for NHL. PoC manufactured CD19 CAR T cells demonstrated manageable toxicity and encouraging early efficacy in Vietnamese patients with R/R ALL and NHL. This model offers a cost-effective strategy for delivering advanced therapy in resource-limited settings.

Fields of Study & Subjects

CAR-T cell therapy research Acute Lymphoblastic Leukemia research Biomedical Ethics and Regulation

Publication details

Journal / source
Molecular Therapy Oncology
Publisher
Elsevier BV
Volume
34
Issue
1
Pages
201156–201156
Publication date
14 February 2026
Language
EN